**Analytical Methods and Validation of Miglitol and Voglibose: An Overview**

Smita Suthar, Aman Naskar, Dipti Pal, Sanmati K Jain\*

Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G.), India

E-mail address: [sanmatijain72@yahoo.co.in](mailto:sanmatijain72@yahoo.co.in) (S.K. Jain); ORCID ID: 0000-0002-4798-7151

**ABSTRACT**

Diabetes mellitus (DM) is a metabolic condition caused by problems with insulin secretion or activity that affects protein, lipid, and carbohydrate metabolism. As the disease progresses, severe diabetes side effects such as retinopathy, neuropathy, nephropathy, cardiovascular problems, and ulceration may emerge. Type 1 and Type 2 Diabetes mellitus, the two main kinds, have different pathogenic characteristics. T1DM is characterised by a failure to produce enough insulin because of the loss of pancreatic beta cells, which is frequently linked to autoimmune disease. T2DM increases the risk of microvascular and macrovascular problems due to insulin resistance and reduced insulin production. Various anti-diabetic drug classes, such as alpha-glucosidase inhibitors like miglitol and voglibose for the control of T2DM, are available as treatment alternatives. These drugs lower carbohydrate absorption, lowering postprandial blood glucose levels. The identification, classification, and determination of drug compounds and products are made possible by analytical method and validation, which are essential in the field of pharmaceutical research. The application of the analytical method is validated to confirm that it is suitable and secure for a certain purpose. Spectroscopic method such as UV-Visible spectroscopy, chromatographic method including HPLC, UPLC and hyphenated methods including LC-MS, LC-FD, LC-FD are employed as analytical method and validation techniques for drug miglitol and voglibose.

**KEYWORDS:** Analytical method, Validation, Miglitol, Voglibose, Diabetes Mellitus

**I. INTRODUCTION**

**A. Diabetes Mellitus**

Diabetes mellitus (DM) is a metabolic disease caused by a problem with the release of insulin, its action, or both. Chronic hyperglycemia caused by insulin deficiency also creates issues with protein, lipid, and the breakdown of carbohydrates. Tissue or vascular damage develops when the illness increases, which can result in serious diabetic side effects such as retinopathy, neuropathy, kidney disease, cardiovascular issues, and ulcers [1]. Although the two main etiopathogenetic categories of type 1 diabetes and type 2 diabetes account for the vast majority of diabetes cases [2].

Type 1 diabetes mellitus, also known as autoimmune diabetes, is a chronic illness that produces hyperglycemia due to an inability to produce adequate insulin due to the loss of pancreatic beta cells [3,4].

Insulin resistance and reduced insulin secretion are the most common anomalies in T2DM. People with T2DM are at a high risk for both microvascular and macrovascular problems due to hyperglycemia and some aspects of the insulin resistance (metabolic) syndrome [5,6,7].

Anti-diabetic drugs are classified into several types, and the decision is influenced by the type of diabetes, the patient's age and circumstances, among other factors. Treatment possibilities include medicines that increase pancreatic insulin production, increase insulin sensitivity in target organs, and decrease glucose absorption from the gastrointestinal tract [8,9,10].

Oral hypoglycaemic agents include thiazolidinediones, biguanides, alpha glucosidase, DPP‐IV inhibitors etc for treatment of T2DM [11,12,13,14,15,16].

**B. Alpha glucosidase inhibitor**

A type of anti-diabetic medicine known as alpha-glucosidase inhibitors (AGIs) is used to treat type 2 diabetes mellitus. They hinder the gut's ability to absorb carbohydrates, a complex form of sugar. AGIs are a distinct class of oral hypoglycaemic medications (OHAs) that have been authorised for the management and prevention of T2DM. Acarbose, miglitol, and voglibose are the three types of AGIs that are currently offered for the treatment of T2DM. All three AGIs work by vying with oligosaccharides in the brush border of the small intestine for the binding of the active centres of the a-glucosidase enzyme. By preventing postprandial glycemia peaks and delaying the rate of digestion of consumed carbohydrates, this decreases postprandial blood glucose and insulin levels [17, 18, 19, 20, 21].

**1. Miglitol**

An α-glucosidase inhibitor, miglitol reduces postprandial glucose concentrations, which are closely connected with the amount of carbohydrates in the diet. Miglitol works by delaying the absorption of complex carbohydrates in the small intestine. Miglitol side effects include gas, diarrhoea, and abdominal pain; they are minor and temporary. With a tiny initial dose that is gradually increased as tolerated, the incidence of digestive issues may be decreased [22].

**Pharmacokinetics of miglitol**

When used as monotherapy, miglitol is typically well tolerated and is not linked to body weight increase or hypoglycemia. The medication is quickly eliminated from the body via the kidneys without being metabolised in any way. Although miglitol is not linked to hypoglycemia, concurrent usage with other oral antidiabetic medications could be reason for changing the dosage of those medications. In long-term investigations, miglitol demonstrated no appreciable effects on renal, respiratory, cardiovascular, or haematological indicators [23].

**2. Voglibose**

Since 1994, it has been a commercially viable DM treatment in Japan. Voglibose's anti-hypoglycaemic effect is caused by a reversible suppression of the glycosidase hydrolyse enzymes in the brush border of the small intestine, which hydrolyse oligosaccharides and disaccharides to glucose and other monosaccharides. Voglibose inhibits the digestion and absorption of dietary polysaccharides by temporarily impeding the activity of enzymes that break down carbohydrates, such as maltase, sucrose, and zomaltase.[24]

**Pharmacokinetics of voglibose**

After oral treatment, voglibose is slowly and ineffectively absorbed; at therapeutic dosages, plasma concentrations are typically undetectable. After intake, the majority of the active, unaltered medicine is still present in the lumen of the digestive tract, where intestinal enzymes and microbial flora break it down. To yet, no active metabolites have been found. Voglibose has a minimal renal excretion and is promptly eliminated in faeces [25].

**C. Analytical Method Development and Validation**

**1. Analytical method development**

The development and validation of analytical methods is critical to the discovery, development, and manufacture of pharmaceuticals [26]. An analytical technique is meant to compare a specific property of the drug substance or drug products to predetermined acceptance criteria for that characteristic [27]. Spectral, chromatographic, electrochemical, hyphenated, or other analytical methods are all possible. Development of analytical methods is the process of choosing an exact assay method to ascertain a formulation's composition [28].

**Figure 1: General analytical methods**

**Purpose of analytical method development**

Drug analysis involves the identification, classification, and determination of pharmaceuticals in combinations such as dosage forms and biological fluids. The fundamental purpose of analytical methods employed in manufacturing and medication development is to offer information about potency, impurity, bioavailability, stability, and the effect of manufacturing parameters in order to ensure that the product is as safe as feasible [29].

**Steps of analytical method development**

**Figure 2: Steps of method development**

Developed method must be validated. To do this, "Analytical Instrument Qualification" must first be carried out, which entails four primary phases: design qualification, installation qualification, operational qualification, and performance qualification [30].

**2. Validation**

The objective of validating an analytical method is to demonstrate that it is appropriate for the task at hand. The following are typical validation criteria recommended by the FDA, USP, and ICH [31].

**Figure 3: Validation parameters**

**B. SPECTROPHOTOMETRIC METHOD**

**UV-Visible spectroscopy as analytical method for miglitol and voglibose [32, 33, 34].**

UV-VIS spectroscopy is a spectrophotometric technique that measures the intensity of light as a function of wavelength in the UV (100-400 nm) and VIS (400-800 nm) regions. It is regarded as the oldest analytical technique. After the analyte absorbs light of a specific wavelength of UV and VIS only, the amount of radiation absorbed by the analyte is measured. The interaction of UV-VIS EMR with the analyte produces the spectrum after UV-VIS light has been absorbed.

**Principle**

UV-VIS spectroscopy, which is based on the phenomenon of light absorption, assesses the concentration of analytes in a sample solution by measuring the amount of absorbed light. Absorption increases as analyte concentration increases.

**Electronic Transitions**

The absorption of electronic energy levels by an organic molecule is linked to the stimulation of valence electrons from the ground state to the excited state. After energy absorption, electronic transitions normally occur from the excited state, which possesses the highest molecular orbital.

**Types of Electronic Transitions**

1**.** σ - σ\*

2. pi - pi\*

3. n - σ\*

4. n - pi\*

**Components of UV-VIS Spectrophotometer**

**Figure 4: Components of UV-VIS Spectrophotometer**

**Table No. 1: UV Visible spectroscopy of miglitol and voglibose**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Drugs** | **Solvent** | **λmax** | **Linearity(μg/ml)** | **LOD(μg/ml)** | **LOQ(μg/ml)** | **Ref** |
| Voglibose | Methanol  (taurine & sodium periodate) | 282nm | 10-80 μg/ml. | - | - | [35] |
| Miglitol + Acarbose |  | 525nm and 610 nm |  | 0.179 (Miglitol)  0.269 (Acarbose) | 0.189 (Miglitol)  0.630 (Acarbose) | [36] |
| Miglitol + metformin |  | 300nm, 270nm,  240nm and 210nm | 0.2-1.2 (miglitol)  2-12 (metformin) | - | - | [37] |
| Voglibose | Water (Taurine and Sodium periodate) | 222nm | 0.003 – 0.024 | 0.00263 | 0.0079 | [38] |
| 235nm | 0.00114 | 0.0034 |
| Metformin + voglibose | Methanol  (Taurine and  Sodium  periodate) | 220nm (metformin) | 10-50 (metformin) | 0.86 (metformin) | 5.11 (metformin) | [39] |
| 242nm (Voglibose) | 2-10 (Voglibose) | 0.62 (Voglibose) | 2.25 (Voglibose) |

LOQ: Limit of quantitation; LOD: Limit of Detection

**C. CHROMATOGRAPHY METHOD**

**1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD**

**HPLC as analytical method for miglitol and voglibose [40, 41, 42, 43, 44].**

Chromatography, in all of its variants, is frequently employed as a separating and analytical method. HPLC, which evolved from classical column chromatography, is currently one of the most important tools in analytical chemistry. The main and essential analytical instrument used in all phases of drug discovery, development, and production is HPLC. HPLC is the primary method for verifying the peak purity of new chemical entities, tracking reaction changes during scale-up or synthesis processes, evaluating new formulations, and performing quality control and assurance on completed pharmaceutical products.

**Goal of HPLC**

Quantify the primary drug, all impurities from processes, all synthetic intermediates that are easily available, and any degradants.

**Principle**

The stationary phase, or sample solution, is injected into a porous column, while the mobile phase, or liquid phase, is pumped through the column at a greater pressure. The separation principle employed is adsorption of solute on stationary phase based on its affinity for stationary phase.

**Instrumentation**

**Figure 5: Instrumentation of HPLC**

**Table No. 2: HPLC of miglitol and voglibose**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **Detection** | **MP** | **SP** | **Linearity(μg/ml)** | **LOD(μg/ml)** | **LOQ(μg/ml)** | **Ref** |
| Metformin + voglibose + pioglitazone | 232nm | 0.1% v/v  acetonitrile:  triethylamine  (30:70, v/v) | cosmosil C18 with Autochro-  3000 software | Metformin = 200-600 | Metformin = 5.45 | Metformin = 16.52 | [45] |
| Voglibose = 0.08-  0.24 | Voglibose = 0.0032 | Voglibose = 0.0097 |
| Pioglitazone = 30-  90 | Pioglitazon = 0.93 | Pioglitazone = 2.83 |
| Voglibose | 282nm | potassium dihydrogen phosphate: acetonitrile: methanol |  | 100 to 500 | 30 | 100 | [46] |
| Repaglinide and voglibose | 255nm | Methanol and dihydrogen phosphate buffer |  | 2-18 | Repaglinide = 0.18  Voglibose = 0.52 | Repaglinide = 0.32  Voglibose = 0.87 | [47] |
| Metformin + voglibose + glimepiride | 230nm | **solution A**  0.02 M Phosphate buffer  **solution B**  Diluent: Water:  acetonitrile (50:50). | Inertsil ODS 3V column | Metformin = 200-600 | Metformin = 0.05 | Metformin = 1.5 | [48] |
| Voglibose = 0.08-0.24 | Voglibose = 0.004 | Voglibose = 0.012 |
| Glimepiride = 0.8 - 2.4 | Glimepiride = 0.002 | Glimepiride = 0.006 |
| Miglitol | - | Acetonitrile and 0.02M Phosphate buffer |  | Linear relationship with r2 found to be >0.9987 | 0.3 | 0.98 | [49] |
| Miglitol | 210nm | Phosphoric acid and acetonitrile buffer |  | Linear relationship with r2 found to be 0.999 | - | - | [50] |
| Miglitol | 220nm | Acetonitrile and monobasic sodium phosphate |  | Linear relationship with r2 = 0.9986 | 5.8 | 18.7 | [51] |
| Miglitol | 216nm | 0.05M ammonium acetate | - | Linear relationship with r2 = 0.996 | 20 | 70 | [52] |
| Miglitol | - | Sodium  1-octanesulfonate as an ion-pair reagent |  | 10 – 2500 | - | - | [53] |
| Miglitol+ Metformin | 236nm | Water: methanol |  | 2.5 to 7.5 (miglitol)  25 to 75 for (metformin) | 0.6607  (miglitol)  1.740  (metformin) | 2.0021  (miglitol)  5.2736 (metformin) | [54] |
| Miglitol + metformin | 238nm | Phosphate buffer and methanol |  | 200-500 (miglitol)  20-50 (metformin) | 100 (miglitol)  30 (metformin) | 0.82  (miglitol)  0.25 (metformin) | [55] |
| Miglitol | 270nm | phosphate buffer- methanol |  | Linear relationship with r2 = 0.9999 | 0.05 | 0.15 | [56] |
| Voglibose | - | Acetonitrile and water (50:50) | C18 column | 10‐100 | 2.91 | 9.7 | [57] |
| Voglibose | - | Acetonitrile: water (20:80 v/*v*) | Agilent TC C18  5μm column | 10-70 | 0.037 | 0.114 | [58] |
| Voglibose | - | Acetonitrile: water (70:30 v/v) | C18 column | 10-60 | 0.054 | 0.16 | [59] |
| Voglibose + metformin | - | 0.02M KH2PO4: ACN  (50:50 v/v) | Hypersil BDS  C18 column | Voglibose = 0.3-0.18 |  | - | [60] |
| Metformin = 50-300 |
| Voglibose + metformin | - | ACN: Buffer pH - 6.5  (62:38 v/v) | C18:250X4.6m  m, 5μ, amino SS  Column | Voglibose = 0.30-0.90 |  | - | [61] |
| Metformin = 500 - 1500 |
| Voglibose + metformin | - | Buffer: ACN (380:620) | C18:250X4.6m  m, 5μ, amino SS  Column | Voglibose = 0.30-0.90 |  | - | [62] |
| Metformin = 500-1500 |
| Voglibose + metformin | - | Phosphate Buffer: ACN = 65: 35 | Waters ODS  (C18) RP  Column | Voglibose = 10-60 | Voglibose = 0.06 | Voglibose = 0.18 | [63] |
| Metformin = 5-40 | Metformin = 0.08 | Metformin = 0.24 |
| Voglibose + repaglinide | - | KH2PO4 Buffer, pH 3.5:  Methanol (30:70%v/v) | Waters ODS  (C18) RP  Column | Repaglinide = 7.5 - 22.5 | Repaglinide = 0.541 | Repaglinide = 1.639 | [64] |
| Voglibose = 4.5 - 13.5 | Voglibose =  0.38 | Voglibose = 1.171 |

LOQ: Limit of quantitation; LOD: Limit of Detection; SP: Solid phase; MP: Mobile phase

**2. ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY METHOD**

**UPLC as analytical method for miglitol and voglibose [65].**

Modern techniques such as UPLC give liquid chromatography a new lease on life. UPLC, or ultra performance liquid chromatography, is a technology that increases in three areas: "speed, resolution, and sensitivity." UPLC is superior than HPLC for particles with diameters smaller than 2 m and can achieve greater resolution, speed, and sensitivity. Analytical laboratories are not immune to this trend, as UPLC analysis now yields higher-quality data. Separation and quantification in UPLC are performed at extremely high pressures (up to 100M Pa).

**Table No. 3: UPLC of miglitol and voglibose**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **SP** | **MP** | **Linearity(μg/ml)** | **LOD(μg/ml)** | **LOQ(μg/ml)** | **Ref.** |
| Miglitol |  | Acetonitrile and ammonium acetate with formic acid. | 150–4000 | - | 150 | [66] |
| Metformin + Voglibose + glimepiride | Inertsil  ODS | Buffer (pH  3.0):  Methanol  (70:30v/v). | Metformin = 300 – 700 | Metformin = 2.98 | Metformin = 9.97 | [67] |
| Glimepiride = 0.6-  1.4 | Glimepiride = 2.95 µg/ml | Glimepiride = 9.97 |
| Voglibose = 0.12-  0.28 | Voglibose = 2.97 | Voglibose = 9.98 |

LOQ: Limit of quantitation; LOD: Limit of Detection; SP: Solid phase; MP: Mobile phase

**D. HYPHENATED TECHNIQUES**

**Hyphenated techniques as analytical method for miglitol and voglibose [68].**

**LC/MS**

Over the past ten years, the use of high-performance liquid chromatography and mass spectrometry (LC/MS) has significantly impacted drug development. Techniques based on liquid chromatography/mass spectrometry (LC/MS) offer special possibilities for pharmaceutical analysis. Sensitivity, selectivity, speed of analysis, and cost effectiveness are just a few of the outstanding analytical methods of merit that make LC/MS procedures useful for a wide range of pharmaceutically relevant substances. These analytical functions have continuously advanced, making instruments more user-friendly and trustworthy. These advancements came at the right time and corresponded with the previously mentioned developments in the pharmaceutical industry. There are four technical factors that have been crucial for the recent acceptance of LC/MS-based procedures in the pharmaceutical business, together with time and perception difficulties.

1. Sciences of separation

2. Mass spectrometry

3. Information

4. Widened scope of application

**Table No. 4: Hyphenated techniques of miglitol and voglibose**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **Methods** | **SP** | **MP** | **Linearity(μg/ml)** | **LOD(μg/ml)** | **LOQ(μg/ml)** | **Ref.** |
| Miglitol | LC-MS | - | Ammonium acetate | Good linearity with r2 ≥ 0.9986 | 1 | 5 | [69] |
| Miglitol | LC-MS | - | Ammonium acetate and acetonitrile - methanol | Linear relationship with r2 = ≥ 0.9984 | - | 0.5 | [70] |
| Miglitol + metformin | LC-MS | - | Ammonium acetate and miglitol | 25–4000  (Miglitol)20–2000 (Metformin) | 7.08  (Miglitol)  3.83 (Metformin) | 22.91 (Miglitol)  10.82 (Metformin) | [71] |
| Voglibose | LC-MS | Waters X Terra MS C18  5 **μ**m column | **solution A =** formic acid in water and **solution B =** formic acid in  methanol  (50:50) | 25.0-1200 | 1.5 | 3.0 | [72] |
| Voglibose | LC-VD | Novapak  C18  column | Buffer (0.01M mixture of sodium  di hydrogen orthophosphate and  disodium hydrogen  orthophosphate) and  acetonitrile (35:65 v/v) | LC-VD – 20 –  30 | - | - | [73] |
| LC-MS | Venusil  XBPPH  column | 0.01%  formic acid and  methanol (95:5 v/v) |
| Voglibose | LC-FD | Cosmosil® 5NH2-MS  column | Acetonitrile and NaH2PO4 (2:1 v/v) | 50–1000. | 9.4 | 29 | [74] |
| LC-MS | 10mM aqueous  NH4OAc  and acetonitrile  (3:7v /v) | 18 | 52 |

LOQ: Limit of quantitation; LOD: Limit of Detection; SP: Solid phase; MP: Mobile phase

**E. CONCLUSION**

This overview discusses on the importance of diabetes mellitus as a metabolic disorder that affects protein, lipid, and carbohydrate metabolism as a result of problems with insulin secretion or action. They concentrate particularly on T2DM and the use of alpha-glucosidase inhibitors, such as miglitol and voglibose, as therapy alternatives to manage T2DM by decreasing postprandial blood glucose levels by delaying the absorption of carbohydrates. This study has highlighted the value of developing and validating analytical methods in pharmaceutical research. The identification, classification, and determination of drug compounds and products, including miglitol and voglibose, has been discussed using a variety of analytical techniques, including UV-Visible spectroscopy, high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and hyphenated techniques like LC-MS. The overview emphasizes the need for proper validation of analytical methods to ensure their suitability and safety for specific purposes. Parameters recommended by regulatory agencies like FDA, USP, and ICH are mentioned for conducting method validation effectively. Overall, a comprehensive overview of the analytical methods and validation techniques used for miglitol and voglibose, which are crucial in pharmaceutical research and development has been provided. The information presented here can serve as a valuable reference for researchers and scientists working in the field of diabetes mellitus and anti-diabetic drug development.

**F. REFERENCES**

1. S. Bastaki, “Diabetes Mellitus And Its Treatment,” Dubai Diabetes And Endocrinology Journal, 13(3), 2005, Pp. 111-134. [Https://Doi.Org/10.1159/000497580](https://doi.org/10.1159/000497580)
2. U. Alam, O. Asghar, S. Azmi, & R. A. Malik, “General Aspects Of Diabetes Mellitus,” Handbook Of Clinical Neurology, 126, 2014, Pp. 211-222.[Https://Doi.Org/10.1016/B978-0-444-53480-4.00015-1](https://doi.org/10.1016/B978-0-444-53480-4.00015-1)
3. A. Katsarou, S. Gudbjörnsdottir, A. Rawshani, D. Dabelea, E. Bonifacio, B. J. Anderson, Et Al., “Type 1 Diabetes Mellitus,” Nature Reviews Disease Primers, 3(1), 2017, Pp. 1-17. Https://Doi.Org/10.1038/Nrdp.2017.16
4. L. Eiselein, H. J. Schwartz, & J. C. Rutledge, “The Challenge Of Type 1 Diabetes Mellitus,” Ilar Journal, 45(3), 2004, Pp. 231-236. [Https://Doi.Org/10.1093/Ilar.45.3.231](https://doi.org/10.1093/ilar.45.3.231)
5. R. A. Defronzo, E. Ferrannini, L. Groop, R. R. W. H. Henry, Et Al., “Type 2 Diabetes Mellitus,” Nature Reviews Disease Primers, 1(1), 2015, Pp. 1-22. [Https://Doi.Org/10.1038/Nrdp.2015.19](https://doi.org/10.1038/nrdp.2015.19)
6. A. B. Olokoba, O. A. Obateru, & L. B. Olokoba, “Type 2 Diabetes Mellitus: A Review Of Current Trends,” Oman Medical Journal, 27(4), 2012, Pp. 269. Doi: [10.5001/Omj.2012.68](https://doi.org/10.5001%2Fomj.2012.68)
7. J. L. Leahy, “Pathogenesis Of Type 2 Diabetes Mellitus” Archives Of Medical Research, 36(3), 2005, Pp. 197-209. [Https://Doi.Org/10.1016/J.Arcmed.2005.01.003](https://doi.org/10.1016/j.arcmed.2005.01.003)
8. P. B. Mane, R. V. Antre, & R. J. Oswal, “Antidiabetic Drugs: An Overview,” Int. J. Pharm. Chem. Sci, 1(1), 2012, Pp. 301-6.
9. L. H. Bosenberg, And Danie Gerhardus Van Zyl, "The Mechanism Of Action Of Oral Antidiabetic Drugs: A Review Of Recent Literature." Journal Of Endocrinology, Metabolism And Diabetes In South Africa 13, No. 3 2008, Pp. 80-88.
10. B. Lorenzati, C. Zucco, S. Miglietta, F. Lamberti, & G, “Bruno Oral Hypoglycemic Drugs: Pathophysiological Basis Of Their Mechanism Of Action,” Pharmaceuticals, 3(9), 2010, Pp. 3005-3020. [Https://Doi.Org/10.3390/Ph3093005](https://doi.org/10.3390/ph3093005)
11. 11 C. Day, "Thiazolidinediones: A New Class Of Antidiabetic Drugs." Diabetic Medicine 16, No. 3, 1999, Pp. 179-192. [Https://Doi.Org/10.1046/J.1464-5491.1999.00023.X](https://doi.org/10.1046/j.1464-5491.1999.00023.x)
12. I. Idris, & R. Donnelly, “Dipeptidyl Peptidase‐Iv Inhibitors: A Major New Class Of Oral Antidiabetic Drug,” Diabetes, Obesity And Metabolism, 9(2), 2007, Pp. 153-165. [Https://Doi.Org/10.1111/J.1463-1326.2007.00705.X](https://doi.org/10.1111/j.1463-1326.2007.00705.x)
13. G. Schäfer, “Biguanides,” A Review Of History, Pharmacodynamics And Therapy. Diabete & Metabolisme, 9(2), 1983, Pp. 148-163.
14. R. K. Campbell, J. R. White Jr, & B. A. Saulie, “Metformin: A New Oral Biguanide,” Clinical Therapeutics, 18(3), 1996, Pp. 360-371. [Https://Doi.Org/10.1016/S0149-2918(96)80017-8](https://doi.org/10.1016/S0149-2918(96)80017-8)
15. O. Mehrpour, F. Saeedi, C. Hoyte, A. Hadianfar, S. Nakhaee, & J. Brent, “Distinguishing Characteristics Of Exposure To Biguanide And Sulfonylurea Anti-Diabetic Medications In The United States,”  The American Journal Of Emergency Medicine, 56, 2022, Pp. 171-177. [Https://Doi.Org/10.1016/J.Ajem.2022.03.023](https://doi.org/10.1016/j.ajem.2022.03.023)
16. S. Kalra, “Alpha Glucosidase Inhibitors,” Jpma. The Journal Of The Pakistan Medical Association, 64(4), 2014, Pp. 474-476.
17. M. Akmal, & R. Wadhwa, “Alpha Glucosidase Inhibitors”, 2020.
18. F. A.Van De Laar, P. L. Lucassen, R. P. Akkermans, E. H. Van De Lisdonk, G. E. Rutten, & C. Van Weel, “Alpha‐Glucosidase Inhibitors For Type 2 Diabetes Mellitus,” Cochrane Database Of Systematic Reviews, (2), 2005.
19. H. Bischoff, “The Mechanism Of Alpha-Glucosidase Inhibition In The Management Of Diabetes,” Clinical And Investigative Medicine. Medecine Clinique Et Experimentale, 18(4), 1995, Pp. 303-311.
20. M. S. Hedrington, & S. N. Davis, “Considerations When Using Alpha-Glucosidase Inhibitors In The Treatment Of Type 2 Diabetes,” Expert Opinion On Pharmacotherapy, 20(18), 2019, Pp. 2229-2235. [Https://Doi.Org/10.1080/14656566.2019.1672660](https://doi.org/10.1080/14656566.2019.1672660)
21. S. R. Joshi, E. Standl, N. Tong, P. Shah, S. Kalra, & R. Rathod, “Therapeutic Potential Of Α-Glucosidase Inhibitors In Type 2 Diabetes Mellitus: An Evidence-Based Review,” Expert Opinion On Pharmacotherapy, 16(13), 2015, 1959-1981. [10.1517/14656566.2015.1070827](https://doi.org/10.1517/14656566.2015.1070827)
22. L. Zhang, Q. Chen, L. Li, J. S. Kwong, P. Jia, P. Zhao, & X. Sun, “Alpha-Glucosidase Inhibitors And Hepatotoxicity In Type 2 Diabetes: A Systematic Review And Meta-Analysis,”  Scientific Reports, 6(1), 2016, 32649.Https://Doi.Org/10.1038/Srep32649
23. L. K. Campbell, D. E. Baker, & R. K. Campbell, “Miglitol: Assessment Of Its Role In The Treatment Of Patients With Diabetes Mellitus,” Annals Of Pharmacotherapy, 34(11), 2000, 1291-1301. [Https://Doi.Org/10.1345/Aph.19269](https://doi.org/10.1345/aph.19269)
24. L. J. Scott, & C. M. Spencer, “Miglitol: A Review Of Its Therapeutic Potential In Type 2 Diabetes Mellitus,” Drugs, 59(3), 2000, 521-549. [Https://Doi.Org/10.2165/00003495-200059030-00012](https://doi.org/10.2165/00003495-200059030-00012)
25. A. S. Dabhi, N. R. Bhatt, & M. J. Shah, “Voglibose: An Alpha Glucosidase Inhibitor,” Journal Of Clinical And Diagnostic Research: Jcdr, 7(12), 2013, 3023.[10.7860/Jcdr/2013/6373.3838](https://doi.org/10.7860%2FJCDR%2F2013%2F6373.3838)
26. K. Kaku, “Efficacy Of Voglibose In Type 2 Diabetes,” Expert Opinion On Pharmacotherapy, 15(8), 2014, 1181-1190. [Https://Doi.Org/10.1517/14656566.2014.918956](https://doi.org/10.1517/14656566.2014.918956)
27. J. Breaux, K. Jones, & P. Boulas, “Analytical Methods Development And Validation,” Pharm. Technol, 1, 2003, 6-13.
28. A. Procedures, “Methods Validation For Drugs And Biologics,” Guidance For Industry. Food And Drug Administration, 2015.
29. A. Chauhan, B. Harti Mittu P. Chauhan Analytical, “Method Development And Validation: A Concise Review,” J Anal Bioanal Tech, 6(233), 2015, 2. Doi: 10.4172/2155-9872.1000233
30. P. Ravisankar, C. N. Navya, D. Pravallika, & D. N. Sri, “A Review On Step-By-Step Analytical Method Validation,” Iosr J Pharm, 5(10), 2015, 7-19.
31. P. S. Singh, & G. Shah, “Analytical Method Development And Validation”  J Pharm Res2011, 4(5), 2011, 2330-2.
32. Chauhan, A. (2015). Harti Mittu B, Chauhan P (2015) Analytical Method Development And Validation: A Concise Review. J Anal Bioanal Tech, 6(233), 2. Doi: 10.4172/2155-9872.1000233
33. M. Picollo, M. Aceto, & T. Vitorino, “Uv-Vis Spectroscopy,” Physical Sciences Reviews, 4(4), 2018, 20180008.
34. H. Förster, “Uv/Vis Spectroscopy,” Characterization I: 2004, 337-426.
35. H. H. Perkampus, “Uv-Vis Spectroscopy And Its Applications,” Springer Science & Business Media, 2013.
36. N. M. Rao, J. Bagyalakshmi, & T. K. Ravi, “Development And Validation Of Uv-Spectroscopic Method For Estimation Of Voglibose In Bulk And Tablets,” J Chem Pharm Res, 2(2), 2010, 350-56.
37. F. A. Ibrahim, F. A. Ali, S. M. Ahmed, & M. M. Tolba, “Kinetic Determination Of Acarbose And Miglitol In Bulk And Pharmaceutical Formulations Using Alkaline Potassium Permanganate,” International Journal Of Biomedical Science: Ijbs, 3(1), 2007, 20.
38. S. R. Patel, P. V. Kabra, R. V. Kimbahune, R. Markad, & L. V. G Nargund, “Development And Validation Of Analytical Method For Quantitative Estimation Of Miglitol And Metformin In Combined Dosage Form,” Journal Of Applied Pharmaceutical Science, 2(7), 2012, 227-229.
39. T. B. Sadhana, K. M. Shrinivas, P. K. Supria, & K. R. Swapna, “Spectrophotometric Determination Of Voglibose In Bulk And Tablet Dosage Form By Absorption Maxima, First Order Derivative Spectroscopy And Area Under Curve Method,” Int J Pharm Res Dev, 5, 2013, 200-6.
40. H. D. Patel, J. Surati, Z. Dedania, S. M. Vijyendraswamy, “Simultaneous Estimation Of Voglibose And Metformin Hydrochloride In Tablet Dosage Form,” V-4, I-1, 2015
41. S. K. Bhardwaj, K. Dwivedia, & D. D. Agarwala, “A Review: Hplc Method Development And Validation" International Journal Of Analytical And Bioanalytical Chemistry, 5(4), 2015, 76-81.
42. P. K. Sahu, N. R. Ramisetti, T. Cecchi, S. Swain, C. S. Patro, & J. Panda, “An Overview Of Experimental Designs In Hplc Method Development And Validation,” Journal Of Pharmaceutical And Biomedical Analysis, 147, 2018, 590-611.
43. M. P. N. Patil, “Hplc Method Development–A Review,” Journal Of Pharmaceutical Research And Education, 1(2), 2017, 243-260.
44. R. J. Hamilton, & P. A. Sewell, “Introduction To High Performance Liquid Chromatography,” In Introduction To High Performance Liquid Chromatography,1982, Pp. 1-12.
45. K. B. Lynch, A. Chen, & S. Liu, “Miniaturized High-Performance Liquid Chromatography Instrumentation,” Talanta,  177, 2018, 94-103.
46. M. A. Shende, & B. R. Budde, “Novel Rp-Hplc Method Development And Validation For Simultaneous Estimation Of Metformin, Voglibose And Pioglitazone In Bulk And Triple Fixed Drug Combinations Pharmaceutical Dosage Form,” Journal Of Drug Delivery And Therapeutics, 9(1), 2019, 30-37.
47. N. M. Rao, K. R. Kumar, J. Bagyalakshmi, T. K. Ravi, & R. Mogili, “Rp-Hplc Method Development And Validation For Estimation Of Voglibose In Bulk And Tablet Dosage Forms,” Int. J. Res. Pharm. Sci, 1(2), 2010, 190-194.
48. T. K. R. Konatham, N. Vallakeerthi, & A. Masipogu, Method Development And Validation Of Repaglinide And Voglibose In Pure And Pharmaceutical Dosage Form By Using Reverse Phase High Performance Liquid Chromatography, 2020.
49. K. Neelima & Y. R. Prasad, “Analytical Method Development And Validation Of Metformin, Voglibose, Glimepiride In Bulk And Combined Tablet Dosage Form By Gradient Rp-Hplc,” Pharmaceut Meth, 5, 2014, 27-33.
50. S. M. Dhole, P. B. Khedekar, & N. D. Amnerkar, “Validated High Performance Liquid Chromatography Method For Determination Of Miglitol In Tablet Dosage Form,” Journal Of Pharmacy Research, 7(7), 2013, 595-599.
51. K. Balakumaran, M. Janagili, N. Rajana, S. Papureddy, & J. Anireddy, “Development And Validation Of Miglitol And Its Impurities By Rp-Hplc And Characterization Using Mass Spectrometry Techniques,” Scientia Pharmaceutica, 84(4), 2016, 654-671.
52. B. Shrivastava, U. S. Baghel, & M. Sahu, “Stability-Indicating Rp-Hplc Method For Estimation Of Miglitol In Bulk And Tablets. Indian Journal Of Pharmaceutical Sciences,” 72(6), 2010, 781.
53. N. C. & A. Jain, “New Rp-Hplc Method Of Miglitol In Tablet Dosage Form Including Forced Degradation Studies And Estimation In Spiked Rabbit Plasma,” Journal Of Young Pharmacists, 1(4), 2009, 285.
54. P. Nilam, P. Pinkal, & S. Khushbu, “Development And Validation Of Analytical Method For Simultaneous Estimation Of Miglitol And Metformin Hydrochloride In Tablet Dosage Form,” International Journal Of Pharmaceutical Sciences And Research, 5(11), 2014, 4820.
55. H. Asamoto, Y. Nobushi, T. Oi, & K. Uchikura, “Determination Of Miglitol By Column-Switching Ion-Pair Hplc With Tris (2, 2′-Bipyridine) Ruthenium (Ii)-Electrogenerated Chemiluminescence Detection,” Chemical And Pharmaceutical Bulletin, 63(6), 2015, 476-480.
56. Bhoomaiah, B., & Shree, A. J. (2014). Development And Validation Of Rp-Hplc Method For Simultaneous Determination Of Metformin And Miglitol In Bulk And Pharmaceutical Formulation. Int J Pharm Pharm Sci, 6(6), 135-41.
57. K. Basavaiah, & N. Rajendraprasad, “Development And Validation Of Novel Stability-Indicating High-Performance Liquid Chromatography Method For The Determination Of Miglitol In Pharmaceuticals,” The Thai Journal Of Pharmaceutical Sciences, 42(1), 2018, 37-34.
58. L. Karunanidhi, And R. Tirumala, “Determination Of Voglibose In Pharmaceutical Formulations By High Performance Liquid Chromatography Using Refractive Index Detection,” European Journal Of Chemistry 1 (4), 2010, 262‐265; Doi:10.5155/Eurjchem.1.4.262‐265.116
59. C. D. Shubhangi, G. W. Sanjay, And C.B. Mahendra, “Stability Indicating Rp-Hplc Method For Estimation Of Voglibose In Bulk And Tablet Dosage Form,” Pharmacophore 2013, Vol. 4 (5), 158-165,”
60. S. Y. Royal Debnath, Manjunath And T. Hemant Kumar, “Development And Validation Of New Rp-Hplc Method For The Estimation Of Voglibose In Bulk And Pharmaceutical Dosage Form,” International Journal Of Biomedical Research, 11(10), 2020. Doi: [Https://Doi.Org/10.7439/Ijbr](https://doi.org/10.7439/ijbr)
61. M. Gayathri Devi Et Al. “Analytical Method Development And Validation For The Estimation Of Metformin And Voglibose In Bulk And Fixed Dose Combination (Tablets) By Rp-Hplc,” Indo Am. J. P. Sci, 05(02), 2018.
62. K. Sonia And K. Prasad Babu, “Rp-Hplc Analysis Of Metformin Hydrochloride And Voglibose And Study Of Its Different Analytical Parameter,” Ijpsr, Vol. 4(4), 2013, 1469 1474.
63. M.S.Harikrishnan, D.Babu Ananth, “Estimation Of Metformin Hydrochloride And Voglibose In Tablet Dosage Form By Rp-Hplc Method," April 2016.
64. B. Mamatha Et Al. “Method Development, Validation And Forced Degradation Studies Of Voglibose And Metformin In Pure And Pharmaceutical Dosage Form By Rp-Hplc,” Ijpbs, 9 (4), 2019, 29-40. Doi: [Https://Doi.Org/10.21276/Ijpbs.2019.9.4.4](https://doi.org/10.21276/ijpbs.2019.9.4.4)
65. A. M. Patel, V. Kotadiya1, N. Tiwari1, P. Patani, “Development And Validation Of Stability Indicating Rp- Hplc Method For Simultaneous Estimation Of Repaglinide And Voglibose In Its Tablet Dosage Form,” Jetir, Volume 8, Issue 5, May 2021.
66. M. Taleuzzaman, S. Ali, S. J. Gilani, S. S. Imam, & A. Hafeez, “Ultra Performance Liquid Chromatography (Uplc)-A Review,” Austin J Anal Pharm Chem, 2(6), 2015, 1056.
67. R. Jain, O. Lukram, & A. Dwivedi, “Ultra‐Performance Liquid Chromatography Electrospray Ionization–Tandem Mass Spectrometry Method For The Estimation Of Miglitol In Human Plasma Using Metformin As The Internal Standard,”  Drug Testing And Analysis, 3(4), 2011, 255-262.
68. V. N. Kadam Et Al, “Development And Validation Of Analytical Methods For Simultaneous Estimation Of Voglibose, Glimepiride And Metformin Hydrochloride In Bulk And Tablet Dosage Form By Hplc,” Ijppr.Human, Vol. 1(2), 2014, 10-2.
69. M. S. Lee, & E. H. Kerns, “Lc/Ms Applications In Drug Development,” Mass Spectrometry Reviews, 18(3‐4), 1999, 187-279.
70. X. Li, Y. Wang, J. Wang, J. P. Fawcett, L. Zhao, & J. Gu, “Determination Of Miglitol In Human Plasma By Liquid Chromatography/Tandem Mass Spectrometry,” Rapid Communications In Mass Spectrometry: An International Journal Devoted To The Rapid Dissemination Of Up‐To‐The‐Minute Research In Mass Spectrometry, 21(2), 2007, 247-251.
71. A. Mizuno‐Yasuhira, K. Kinoshita, S. Jingu, & J. I. Yamaguchi, “A Sensitive And Selective Method For The Quantitative Analysis Of Miglitol In Rat Plasma Using Unique Solid‐Phase Extraction Coupled With Liquid Chromatography–Tandem Mass Spectrometry” Biomedical Chromatography, 28(10), 2014, 1423-1429.
72. M. V. Attimarad, A. B. Nair, & B. E. Aldhubaib, “Development Of Liquid Chromatographic Method For The Simultaneous Determination Of Metformin And Miglitol In Human Plasma: Application To Pharmacokinetic Studies,” Journal Of The Iranian Chemical Society, 12, 2015,1629-1636.
73. M. Rajput, M. Dahiya, P. Kumari, K. Kalra, M. Aggarwal, & R. K. Khandal, “Method Development And Validation For Determination Of Voglibose In Tablet Formulation Using Lc-Ms/Ms,” Journal Of Chemistry, 8, 2011, 1770-1783.
74. K. Ramakrishnab Et Al. “Development And Validation Of Lc Methods With Visible Detection Using Pre-Column Derivatization And Mass Detection For The Assay Of Voglibose,” 77(5), Mar 15 2009 1869-72. Doi :10.1016/J.Talanta.2008.09.041.
75. J. S. Woo, & J. K. Ryu, “Quantitative Determination Of Voglibose In Pharmaceutical Tablets Using High-Performance Liquid Chromatography–Fluorescence Detection With Post-Column Derivatization And Mass Spectrometric Detection,” Journal Of Pharmaceutical And Biomedical Analysis, 42(3), 2006, 328-333.